Intercept Pharma is a biopharmaceutical brand dedicated to developing and delivering innovative medicines for individuals living with rare and serious liver diseases. Their focus lies in tackling the challenges associated with primary biliary cholangitis (PBC), a progressive autoimmune disease that can lead to cirrhosis or the need for a liver transplant if left untreated. Intercept Pharma's goal is to prevent end-stage liver disease and increase transplant-free survival through their therapeutic treatments.

Driven by a commitment to improving patient lives, Intercept Pharma utilizes a novel scientific platform and targets unique scientific discoveries in the field of liver health. Their pipeline of investigational therapies shows promise in addressing high unmet needs across various liver diseases, including severe alcohol-associated hepatitis. The brand actively conducts clinical trials, knowing that they are pivotal in developing new medicines.

Intercept Pharma's core values encompass collaboration and partnership, as they understand that developing new treatments requires dedication and scientific knowledge. They champion a culture of innovation and provide a supportive work environment for employees who share their passion for making a difference in the lives of patients with rare and serious liver diseases